Physician profile
Julia E Kelley
NPI 1578896338
$6,390.14
in general payments reported to CMS, 2019-2025
37 companies · $2,323 in 2025
The $2,323 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $552 · 2022: $1,659 · 2023: $823 · 2024: $1,034 · 2025: $2,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,173 · Education: $7.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,172.53 |
| Education | $7.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $889.64 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $569.51 | 2022-2025 | Korlym |
| Abbott Laboratories | $471.81 | 2022-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $458.21 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $434.89 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $420.28 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $385.35 | 2021-2025 | Evenity, Repatha, Prolia |
| Dexcom, INC. | $286.52 | 2022-2025 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $269.89 | 2022-2025 | Xyosted |
| Abbvie INC. | $223.71 | 2021-2025 | |
| Tandem Diabetes Care, INC. | $216.93 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Bayer Healthcare Pharmaceuticals INC. | $207.83 | 2022-2025 | |
| Mannkind Corporation | $199.80 | 2021-2025 | |
| Ibsa Pharma INC. | $198.10 | 2022-2025 | Licart, Tirosint, Flector |
| Astrazeneca Pharmaceuticals Lp | $146.05 | 2021-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $125.64 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Alexion Pharmaceuticals, INC. | $120.59 | 2023-2025 | Strensiq |
| Madrigal Pharmaceuticals | $86.78 | 2025 | Rezdiffra |
| Insulet Corporation | $83.36 | 2024-2025 | Omnipod |
| Medtronic, INC. | $78.04 | 2021-2025 | Minimed 780g |
| Radius Health, INC. | $77.79 | 2022-2024 | Tymlos |
| Novartis Pharmaceuticals Corporation | $67.92 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $52.62 | 2023 | |
| Ascensia Diabetes Care US INC. | $35.00 | 2024 | |
| Kyowa Kirin, INC. | $33.93 | 2023 | Crysvita |
| Nevro Corp. | $32.08 | 2021 | |
| Recordati_rare_diseases_inc. | $28.00 | 2022-2025 | Isturisa |
| Beta Bionics, INC. | $27.39 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Sequel Med Tech, LLC | $23.22 | 2025 | Twiist |
| Zealand Pharma US, INC. | $21.84 | 2022 | |
| Amryt Pharma Holdings Ltd | $20.90 | 2021 | |
| Acella Pharmaceuticals, LLC | $20.68 | 2025 | NP Thyroid 60 |
| Amphastar Pharmaceuticals, INC. | $19.22 | 2024 | |
| Lifescan, INC. | $18.27 | 2021 | |
| Cequr Corporation | $14.75 | 2023 | Cequr Simplicity |
| Eusa Pharma (US) LLC | $11.88 | 2022 | |
| Roche Diabetes Care, INC. | $11.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Kelley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.